CC-96191 is a TriNKET® targeting CD33 on AML cells while activating NK cells through the co-engagement of CD16a (Fc gamma receptor IIIa, FcγRIIIA) and NKG2D. Here, FCGR3A is linked to acute myeloid leukemia.